NEW ZEALAND DATA SHEET

1  SOFRAMYCIN 5 MG/ML EAR/EYE DROPS

Soframycin 5 mg/mL Ear/Eye Drops

2  QUALITATIVE AND QUANTITATIVE COMPOSITION

Framycetin sulfate 5 mg/mL (0.55% w/v)

Excipient with known effect: Benzalkonium chloride.

For the full list of excipients, see Section 6.1 List of excipients.

3  PHARMACEUTICAL FORM

Ear/Eye Drops

Soframycin is a clear bright colourless aqueous solution.

4  CLINICAL PARTICULARS

4.1  THERAPEUTIC INDICATIONS

In the eye: Conjunctivitis, blepharitis, styes, corneal abrasions and burns. Prophylactically following removal of foreign bodies. Also indicated for corneal ulcers.

In the ear: Otitis externa.

4.2  DOSE AND METHOD OF ADMINISTRATION

Dose

In the eye: 2 drops every one or two hours initially, diminishing to 2 or 3 drops three times daily.

In the ear: 2 or 3 drops may be instilled into the external auditory meatus thrice daily; or a wick may be saturated with drops.
**Elderly**

No dosage adjustment is necessary.

**Paediatric population**

No dosage adjustment is necessary.

**Method of administration**

For ophthalmic and otic administration.

### 4.3 CONTRAINDICATIONS

Known hypersensitivity to framycetin sulfate or to any of the excipients listed in Section 6.1. Soframycin is contraindicated in case of eardrum perforation.

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

In patients known to be allergic to other aminoglycoside antibiotics (neomycin, paromomycin, kanamycin), cross-sensitisation to framycetin sulfate may occur, but not invariably so.

Aminoglycoside antibiotics may cause irreversible, partial or total deafness when applied topically to open wounds or damaged skin. This effect is aggravated by renal or hepatic impairment and by prolonged duration of treatment. The treatment should not be continued after resolution of symptoms.

Contact with soft contact lenses should be avoided. Contact lenses should be removed prior to application and patients should wait at least 15 minutes before reinsertion. The excipient Benzalkonium chloride is known to discoulour soft contact lenses.

**Use in the elderly**

No data available.

**Paediatric use**

No data available.

**Effects on laboratory tests**

No data available.
4.5 INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION

No data available.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility
No data available.

Pregnancy

Category D

Gentamicin and other aminoglycosides cross the placenta. There is evidence of selective uptake of gentamicin by the foetal kidney resulting in cellular damage (probably reversible) to immature nephrons. Eighth cranial nerve damage has also been reported following in-utero exposure to some of the aminoglycosides. Because of their chemical similarity, all aminoglycosides must be considered potentially nephrotoxic and ototoxic to the foetus. It should also be noted that therapeutic blood levels in the mother do not equate with safety for the foetus.

There are no available data on Soframycin use in pregnant women. No conclusions can be drawn regarding whether or not Soframycin is safe for use during pregnancy. Soframycin should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the foetus.

Breast-Feeding

There are no available data on the presence of Soframycin in human milk, milk production, or the effects on the breastfed infant. No conclusions can be drawn regarding whether or not Soframycin is safe for use during breastfeeding. Soframycin should be used during breastfeeding only if the potential benefits to the mother outweigh the potential risks, including those to the breastfed child.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Use in the eye will cause blurring of the vision on application. Patients should be warned not to drive or operate hazardous machinery unless vision is clear.

4.8 UNDESIRABLE EFFECTS

Hypersensitivity reactions may occur after topical use of aminoglycoside antibiotics (see Section 4.4). Benzalkonium chloride which is used as a preservative in the ear/eye drops can cause irritation to eyes and induce hypersensitivity reactions.
Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions at https://nzphvc.otago.ac.nz/reporting/.

4.9 OVERDOSE

Oral ingestion of the contents of one bottle (up to 8 mL) is unlikely to lead to any serious adverse effects.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

Chemical structure

\[ C_{23}H_{46}N_6O_{13},xH_2SO_4 \quad 615 \text{ (base)} \]

CAS number

The CAS number is 4146-30-9

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antibiotics, ATC code: S01AA07

Framycetin sulfate is an aminoglycoside bactericidal antibiotic. It is active against a wide variety of both Gram-positive and Gram-negative bacteria commonly found in superficial eye infections: staphylococci (including strains resistant to other antibiotics), Pseudomonas aeruginosa, coliform bacteria and pneumococci. It is exceptionally well tolerated by the tissues of the eye. Preparations containing it are non-irritant.
Clinical trials

No data available.

5.2 PHARMACOKINETIC PROPERTIES

Absorption
No data available.

Distribution
No data available.

Metabolism
No data available.

Excretion
No data available.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity
No data available.

Carcinogenicity
No data available.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS
benzalkonium chloride (as a preservative),
citric acid monohydrate,
sodium chloride,
sodium citrate dihydrate
purified water.
6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

3 years

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

6.5 NATURE AND CONTENTS OF CONTAINER

Ear/Eye Drops: 8 mL bottle.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

No special requirements.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

sanofi-aventis new zealand limited
Level 8,
56 Cawley Street
Ellerslie, Auckland
Free Call: 0800 283 684
Email: medinfo.australia@sanofi.com

9 DATE OF FIRST APPROVAL

31 December 1969

10 DATE OF REVISION OF THE TEXT

10 January 2020
Table 1 - Summary of Changes

<table>
<thead>
<tr>
<th>Section</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title, 2; 4; 5; &amp; 6</td>
<td>Editorial</td>
</tr>
<tr>
<td>4.6</td>
<td>Section updated in line with CCDSv3</td>
</tr>
<tr>
<td>5</td>
<td>Chemical structure and CAS number added</td>
</tr>
</tbody>
</table>